Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 3, 2025

Allison Ames, Susan Brandt, Steven Ekstract, Hallmark, Dolly Parton, and Kevin Smith Join Licensing International Hall of Fame

View original at globenewswire.com
Allison Ames, Susan Brandt, Steven Ekstract, Hallmark, Dolly Parton, and Kevin Smith Join Licensing International Hall of Fame NEW YORK, Dec…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dolly Parton's Imagination Library has donated over 302 million books

    80% confidence

  • From industry veterans to global icons, this year's nominees represent the wide-ranging possibilities of brand licensing and its influence across sectors

    80% confidence

  • Dolly Parton has sold more than 100 million records worldwide

    80% confidence

  • The global licensing industry is valued at $369+ billion

    80% confidence

  • The Hall of Fame event unites our global community of leaders and underscores the far-reaching impact of licensing worldwide

    80% confidence

  • The Dr. Seuss brand has grown into a multibillion-dollar franchise under Susan Brandt's leadership

    80% confidence

  • Beanstalk accounted for over $11 billion in retail sales on behalf of its clients in 2024

    80% confidence

  • We're proud to recognize such influential leaders while also celebrating emerging talent through our annual Rising Star Award and the Licensing International Foundation's scholarship program

    80% confidence

  • Under Allison Ames' leadership, Beanstalk has won over 30 industry awards

    80% confidence

  • Beanstalk consistently ranks as the third largest licensing agency in the industry

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com